Astrazeneca gets marketing authorisation to use anti-diabetes drug for kidney disease

Astrazeneca gets marketing authorisation to use anti-diabetes drug for kidney disease The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with CKD, it added. https://ift.tt/eA8V8J